Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects^#

References

• Haserick J, Richardson J, Grant D. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin Q. 1959;26(3):144–147.
   Google Scholar
• Van Scott EJ. Complete regressions of mycosis fungoides with topical mechlorethamine hydrochloride. JAMA. 1972;222(9):1172.
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Van Scott EJ, Wallner PE, et al. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep. 1979;63(4):681–689.
   PubMedGoogle Scholar
• Price NM, Deneau DG, Hoppe RT. The treatment of mycosis fungoides with ointment-based mechlorethamine. Arch Dermatol. 1982;118(4):234–237.
   PubMedGoogle Scholar
• Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988;19(4):684–691.
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Tan ET, Kantor AF, et al. Long- term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):416–428.
   PubMed Web of Science ®Google Scholar
• Kim YH, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the stanford experience. Arch Dermatol. 2003;139(2):165–173.
   PubMedGoogle Scholar
• Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis. J Eur Acad Dermatol Venereol. 2013;27(2):163–168.
   PubMed Web of Science ®Google Scholar
• de Quatrebarbes J, Estève E, Bagot M, et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol. 2005;141(9):1117–1120.
   PubMedGoogle Scholar
• National comprehensive cancer network clinical practice guidelines in oncology. Primary cutaneous lymphomas. Version 1.2020. 2020 [cited 2020 Dec 3]. Available from: https://www.nccn.org/professionals/physician_gls/default_nojava.aspx.
   Google Scholar
• Willemze R, Hodak E, Zinzani PL, ESMO Guidelines Committee, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30–iv40.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/sézary syndrome – update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32.
   PubMed Web of Science ®Google Scholar
• Geskin LJ, Bagot M, Hodak E, et al. Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous t-cell lymphoma: a narrative review and international experience. Dermatol Ther (Heidelb). 2021;11(4):1085–1106.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma . Am J Clin Dermatol. 2021;22(3):407–414.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Geskin L, Guitart J, et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study. J Am Acad Dermatol. 2020;83(3):928–930.
   PubMed Web of Science ®Google Scholar
• Wehkamp U, Jost M, Gosmann J, et al. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. JDDG. 2021;19(7):1057–1059.
   Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Olsen E, Whittaker S, Kim YH, Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–2607.
   PubMed Web of Science ®Google Scholar
• Vonderhied EC. Topical mechlorethamine chemotherapy. Considerations on its use in mycosis fungoides. Int J Dermatol. 1984;23:180–186.
   PubMed Web of Science ®Google Scholar
• Vonderheid EC. Treatment planning in cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4):276–282.
   PubMedGoogle Scholar
• Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4):288–298.
   PubMedGoogle Scholar
• Querfeld C, Scarisbrick JJ, Assaf C, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides. Dermatology. 2021; (4):1–11.
   PubMedGoogle Scholar
• van Santen S, van Doorn R, Neelis KJ, et al. Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch cutaneous lymphoma group. Br J Dermatol. 2017;177(1):223–228.
   PubMed Web of Science ®Google Scholar
• Amitay-Laish I, Prag-Naveh H, Dalal A, et al. Hodak E treatment of early folliculotropic mycosis fungoides with special focus on psoralen plus ultraviolet A. Acta Derm Venereol. 2018;98(10):951–955.
   PubMed Web of Science ®Google Scholar
• Gilmore ES, Alexander-Savio CV, Chung CG, et al. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020;6(9):878–881.
   PubMedGoogle Scholar
• Bergman R, Cohen A, Harth Y, et al. Histopathologic findings in the clinically uninvolved skin of patients with mycosis fungoides. Am J Dermatopathol. 1995;17(5):452–456.
   PubMed Web of Science ®Google Scholar
• El-Darouti MA, Marzouk SA, Bosseila M, et al. Microscopic study of normal skin in cases of mycosis fungoides. Int J Dermatol. 2006;45(9):1043–1046.
   PubMed Web of Science ®Google Scholar
• Price NM. Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration. Arch Dermatol. 1977;113(10):1387–1389.
   PubMedGoogle Scholar
• Flaxman BA, Sosis AC, Van Scott EJ. Changes in melanosome distribution in caucasoid skin following topical application of nitrogen mustard. J Invest Dermatol. 1973;60(5):321–326.
   PubMed Web of Science ®Google Scholar
• Van Scott EJ, Yu RJ. Melanogenesis from topical mechlorethamine and analogues in skin of hairless mice and in vitiligo. J Invest Dermatol. 1975;65(5):476–478.
   PubMed Web of Science ®Google Scholar